Long-circulating iron oxides for MR imaging

Advanced Drug Delivery Reviews

Volumn 16, Issue 2-3, 1995, Pages 321-334

  Weissleder, Ralph ^a   Bogdanov, Alexei ^a   Neuwelt, Edward A ^b   Papisov, Mikhail ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Iron oxide; MR imaging

Indexed keywords

ANGIOGRAPHY; MAGNETIC PROPERTIES; MAGNETIC RESONANCE IMAGING; METABOLISM; PHARMACOKINETICS; SYNTHESIS (CHEMICAL); TOXICITY;

LYMPH NODE IMAGING; NEURONAL TRANSPORT IMAGING; OPSONIZATION; PHARMACOLOGY; TARGET SPECIFIC IMAGING;

IRON OXIDES;

AMINOPHOSPHOLIPID; DEXTRAN; DIAGNOSTIC AGENT; FERROSOME; INDIUM 111; IRON 59; IRON OXIDE; MACROGOL; MION 37; MION 46; POLYLYSINE; POLYMER; TECHNETIUM 99M; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG;

ANGIOGRAPHY; CIRCULATION TIME; CLINICAL TRIAL; DRUG COATING; DRUG HALF LIFE; DRUG TARGETING; HUMAN; INTRACELLULAR TRANSPORT; NERVE CELL; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RETICULOENDOTHELIAL SYSTEM; REVIEW; URTICARIA;

EID: 0029360672     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0169-409X(95)00033-4     Document Type: Review

References (50)

1. Pharmaceutical iron oxides for MR imaging
2. Magnetic microspheres: a model system for site specific drug delivery in vivo
3. Biophysical drug targeting: magnetically responsive albumin microspheres
4. Magnetic drug targeting. I. In vivo kinetics of radiolabelled magnetic drug carriers
5. Magnetic drug targeting. II. Targeted drug transport by magnetic microparticles: factors influencing therapertic effect
6. Magnetic microcapsules for targeted delivery of anticancer drugs
7. Dextran magnetite: a new relaxation agent and its application to T2 measurements in gel systems
8. Contrast agents for magnetic resonance imaging
9. Ferromagnetic particles as contrast agents for magnetic resonance imaging of the liver and spleen
10. Ferromagnetic particles as contrast agents in T2 NMR imaging
11. Magnetite albumin microspheres: a new MR contrast material
12. Ferromagnetic contrast agents a new approach
13. Ferromagnetic antibody relaxation technique
14. The use of dextran-magnetite for liver enhancement
15. Relaxation enhancement of the dog liver and spleen by biodegradable superparamagnetic particles in proton magnetic resonance imaging
16. Ferrite particles: a superparamagnetic MR contrast agent for the reticuloendothelial system
17. Target specific nuclear magnetic resonance imaging with antibody-iron-oxide particles
18. Ultrasmall magnetic particles coated with polyethyleneglycol as contrast agent in MRI of experimental abscesses: an animal study in mini-pigs
19. Ultrasmall superparamagnetic iron oxide: characterization of a new class of contrast agents for MR imaging
20. Ultrasmall superparamagnetic iron oxide: an intravenous contrast agent for assessing lymph nodes with MR imaging
21. Phase 1 clinical evaluation of a new iron oxide MR contrast agent
22. MR antibody imaging antimyosin labelled with monocrystalline iron oxide allows detection of myocardial infarct
23. Enhancement of MR angiography with iron oxide: preliminary studies in whole-blood phantom and in animals
24. Asialofetuin coupled monocrystalline iron oxide as an asialoglycoprotein receptor MR imaging agent
25. Pancreatic receptor initial feasibility studies with a targeted contrast agent for MR imaging
26. MR imaging of slow axonal transport in vivo
27. Polyclonal human immunoglobulin G labeled with polymeric iron oxide: antibody MR imaging
28. Some applications of ferrofluid magnetic colloids
29. Organ and tissue directed MR contrast agents
30. Polymeric iron oxide compounds for MR imaging
31. Formation of Fe(II),Fe(III) intermediary green complex on oxidation of ferrous iron in neutral and slightly alkaline sulphate solutions
32. Effect of particle surface on biodistribution
33. Polymer-inorganic composites produced by matrix condensation of titanium(IV) hydroxide in the presence of polyethylene glycol
34. Trapping of dextran-coated colloids in liposomes by transient binding to aminophospholipid: preparation of ferrosomes
35. Opsonization of dextran stabilized iron oxides with plasma proteins
36. Regulating the fate of mRNA: the control of cellular iron metabolism
37. Superparamagnetic iron oxide: pharmacokinetics and toxicity
38. Single shot echo planar imaging allows assessment of pharmacokinetics of MR contrast agents
39. Hemochromatosis: how much is too much?
40. Haemosiderin and tissue damage
41. Editorial: Liver MR imaging with iron oxides: towards consensus and clinical practice
42. MR lymphography: study of a high-efficiency lymphotropic agent
43. Regional differences in rat brain displayed by fast MRI with superparamagnetic contrast agents
44. Assessment of a superparamagnetic iron oxide (AMI-25) as a brain contrast agent
45. Iron-dextran antibody conjugates: general method for simultaneous staining of two components in high-resolution immuno-electron microscopy
46. Biodistribution of an ultrasmall superparamagnetic iron oxide colloid, BMS 180549, by different routes of administration
47. Antimyosin labeled monocrystalline iron oxide allows detection of myocardial infarct: MR antibody imaging
48. Monocrystalline iron oxide nanocompounds (MION): physicochemical properties
49. Magnetoliposomes: formation and structural characterization
50. MR imaging of MION conjugated carcinoma specific monoclonal antibody in a rodent model of intracerebral human lung cancer The potential for noninvasive diagnosis